1. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes 
M.T. Coughlan, J.M. Forbes, M.E. Cooper 
Kidney International 
Volume 72, Pages S54-S60 (August 2007)
DOI: /sj.ki
Copyright © 2007 International Society of Nephrology Terms and Conditions

2. Figure 1
This figure shows a schema of how various treatments retard the accumulation and the biological effects of AGEs.
Adapted from Forbes et al.20
Kidney International  , S54-S60DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions

3. Figure 2
Data are shown in control (C), diabetic (D), and alagebrium-treated diabetic (DAlt) rats as mean±s.e.m. (a–c) The upper panel shows (a) cytosolic and (b) mitochondrial superoxide production and (c) manganese superoxide dismutase activity. (d–f) The lower panel shows (d) total PKC activity, (e) PKCα phosphorylation and (f) PKCβ immunostaining. *P<0.05 compared to control. #P<0.01 compared to control. †P<0.01 compared to diabetic. ‡P<0.05 compared to diabetic.
Adapted from Thallas-Bonke et al.44 and Coughlan et al.45
Kidney International  , S54-S60DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions